- Investing.com
Metrics to compare | VIVO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVIVOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.0x | 12.0x | −0.4x | |
PEG Ratio | 0.10 | 0.06 | 0.00 | |
Price/Book | 0.4x | 1.7x | 2.6x | |
Price / LTM Sales | 0.7x | 0.8x | 3.0x | |
Upside (Analyst Target) | - | 49.5% | 58.0% | |
Fair Value Upside | Unlock | −5.8% | 7.8% | Unlock |
Vivo Bio Tech Limited provides drug development and discovery services to pharmaceutical and biotech companies worldwide. The company offers services in the areas of in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxic kinetic studies, genotoxicity screening, analytical, and other services. It also supplies specific pathogen free lab animals; breeders and distributes rodent models; and designs and develops of syngeneic / xenograft models for evaluation of anti-cancer agents evaluation, as well as offers custom rodent models, stem cell products, and lab animal diets. In addition, the company provides regulatory and non-regulatory IND preclinical development services; and screening and evaluating molecules for various pharmacological properties. The company was formerly known as Sunshine Factors & Exports Limited and changed its name to Vivo Bio Tech Limited in September 2002. Vivo Bio Tech Limited was incorporated in 1987 and is based in Hyderabad, India.